SRD trial | | | | | | | | | | | | |
Subjects | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | | | | |
Adverse event | | | | | | | | | | | | |
Subjects with any adverse event | 2 (14.3) | 1 (16.7) | 0 | 1 (16.7) | 1 (16.7) | 2 (33.3) | 0 | 1 (16.7) | | | | |
Headache | 1 (7.1) | 1 (16.7) | 0 | 1 (16.7) | 0 | 1 (16.7) | 0 | 0 | | | | |
Nasopharyngitis | 1 (7.1) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (16.7) | | | | |
Cough | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | | | | |
Dry eye | 0 | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | | | | |
Subjects with drug-related adverse events | 0 | 0 | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | | | | |
MRD trial | | | | | | | | | | | | |
Subjects | 10 | | 8 | 8 | 8 | 8 | 8 | | | | | |
Subjects with any adverse event | 1 (10.0) | | 1 (12.5) | 2 (25.0) | 5 (62.5) | 4 (50.0) | 2 (25.0) | | | | | |
Adverse events in ≥2 subjects | | | | | | | | | | | | |
Headaches | 0 | | 1 (12.5) | 0 | 1 (12.5) | 0 | 1 (12.5) | | | | | |
Diarrhoea | 0 | | 0 | 0 | 2 (25.0) | 1 (12.5) | 0 | | | | | |
Oropharyngeal pain | 0 | | 0 | 0 | 2 (25.0) | 0 | 1 (12.5) | | | | | |
Cough | 0 | | 0 | 0 | 0 | 1 (12.5) | 1 (12.5) | | | | | |
Dyspepsia | 0 | | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | | | | | |
Dizziness | 0 | | 0 | 0 | 0 | 2 (25.0) | 0 | | | | | |
Subjects with drug-related adverse events | 0 | | 1 (12.5) | 1 (12.5) | 4 (50.0) | 4 (50.0) | 1 (12.5) | | | | | |
Subjects with adverse events leading to discontinuation of trial drug | 0 | | 0 | 0 | 0 | 1 (12.5) | 0 | | | | | |
Bioavailability trial | | | | | | | | | | | | |
Subjects | | | | | | | | | 12 | 12 | 12 | 12 |
Subjects with any adverse events | | | | | | | | | 2 (16.7) | 0 | 1 (8.3) | 1 (8.3) |
Subjects with serious adverse events (neuropathia vestibularis right) | | | | | | | | | 1 (8.3) | 0 | 0 | 0 |
Subjects with drug-related adverse events | | | | | | | | | 0 | 0 | 0 | 0 |
Subjects with adverse events leading to discontinuation of trial drug | | | | | | | | | 0 | 0 | 0 | 0 |